Risdiplam trials: exciting early results in Firefish – TreatSMA
Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy | NEJM
Early-Onset SPINRAZA® (nusinersen) Efficacy | HCP
Spinraza (nusinersen) for the Treatment of Spinal Muscular Atrophy (SMA) - Clinical Trials Arena
Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophy | Nature Neuroscience
Spinraza – Canada – final drug review | High, apple pie, in the sky, hopes
Cost Effectiveness of Nusinersen in the Treatment of Patients with Infantile-Onset and Later-Onset Spinal Muscular Atrophy in Sweden | SpringerLink
Combinatorial treatment for spinal muscular atrophy - Poletti - 2020 - Journal of Neurochemistry - Wiley Online Library
Later-Onset SPINRAZA® (nusinersen) Efficacy | HCP
Threats to Spinraza are mounting, but Biogen still has cards to play | Evaluate
Ionis's Spinraza Still Bests Novartis's Zolgensma (NYSE:NVS) | Seeking Alpha
Later-Onset SMA (Types 2 & 3)| SPINRAZA® (nusinersen)
Therapeutic approaches for spinal muscular atrophy (SMA) | Gene Therapy
Biogen and Ionis Pharmaceuticals: A Message to the SMA Community - Muscular Dystrophy Association
SMA patients can switch from Spinraza to Zolgensma' < Hospital < 기사본문 - KBR
Later-Onset SMA (Types 2 & 3)| SPINRAZA® (nusinersen)
Risdiplam trials: early results of Sunfish – TreatSMA
Interim results: Infantile-onset SMA | SPINRAZA® (nusinersen) HCP
Spinraza Can Restore Motor Function in Children With Late-Onset SMA, Study Finds
Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study - The Lancet
SPINRAZA® (nusinersen) Safety Profile | HCP
Biogen's Spinraza scores later-onset SMA data for stepped-up push with payers | Fierce Pharma
Spinraza Clinical Trial Update: Boy With Type 1 SMA Progressing Well - SMA News Today
SMA treatment: Novartis and Biogen face lost market opportunities
